Table 3

Association between methylation patterns of MLH1 and MGMT and mutational status
Methylation status Mutational status N (%) p
BRAF V600E*
MLH1 Methylated Positive 4/20 (20%) 0.048
Negative 10/19 (53%)
Unmethylated Positive 16/20 (80%)
Negative 9/19 (47%)
MGMT Methylated Positive 14/20 (70%) 0.333
Negative 10/19 (53%)
Unmethylated Positive 6/20 (30%)
Negative 9/19 (47%)
RET/PTC*
MLH1 Methylated Positive 8/16 (50%) 1.000
Negative 10/19 (53%)
Unmethylated Positive 8/16 (50%)
Negative 9/19 (47%)
MGMT Methylated Positive 9/16 (56%) 1.000
Negative 10/19 (53%)
Unmethylated Positive 7/16 (44%)
Negative 9/19 (47%)
Transitions (IDH1 + NRAS)
MLH1 Methylated Positive 5/11 (45%) 1.000
Negative 13/25 (52%)
Unmethylated Positive 6/11 (55%)
Negative 12/25 (48%)
MGMT Methylated Positive 9/11 (82%) 0.268
Negative 15/25 (60%)
Unmethylated Positive 2/11 (18%)
Negative 10/25 (40%)
Point mutations (BRAF + IDH1 + NRAS)
MLH1 Methylated Positive 14/41 (34%) 0.199
Negative 13/25 (52%)
Unmethylated Positive 27/41 (66%)
Negative 12/25 (48%)
MGMT Methylated Positive 29/41 (71%) 0.426
Negative 15/25 (60%)
Unmethylated Positive 12/41 (29%)
Negative 10/25 (40%)

* Analysis performed only in the PTC group.

Negative group comprises only samples without any of the alterations investigated.

Santos et al.

Santos et al. BMC Cancer 2013 13:79   doi:10.1186/1471-2407-13-79

Open Data